UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercializing antibiotics in the US, announced on 5/15/18 the signature of an exclusive... read more
UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercializing antibiotics in the US, announced on 5/15/18 the signature of an exclusive... read more
Celsius Therapeutics, launched on 5/15/18 with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin... read more
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced on 5/14/18 the addition of new scientific advisors in immuno-oncology and autoimmunity. The advisors hail from prestigious international... read more
Beam Therapeutics announced today that it is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code. Co-founded by scientific pioneers known... read more
UCB announced on 5/14/18 that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company's newest anti-epileptic drug (AED) Briviact (... read more